Itau Unibanco Holding S.A.’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-226
Closed -$1.29K – 549
2023
Q1
$1.29K Hold
226
– – ﹤0.01% 496
2022
Q4
$2.28K Sell
226
-19
-8% -$357 ﹤0.01% 499
2022
Q3
$5K Hold
245
– – ﹤0.01% 518
2022
Q2
$6K Sell
245
-50
-17% -$1.38K ﹤0.01% 440
2022
Q1
$11K Buy
295
+12
+4% +$465 ﹤0.01% 424
2021
Q4
$17K Buy
283
+4
+1% +$227 ﹤0.01% 373
2021
Q3
$17K Buy
279
+8
+3% +$628 ﹤0.01% 344
2021
Q2
$24K Buy
+271
New +$21.8K ﹤0.01% 273

Other funds holding FATE

Itau Unibanco Holding S.A.'s FATE Position: Q2 2023 in Review

Itau Unibanco Holding S.A. sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 226 shares — an estimated $1.29K sold.

Itau Unibanco Holding S.A. first reported a position in FATE in Q2 2021 and held it in 8 quarters. The position peaked at $24K in Q2 2021. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

  • Itau Unibanco Holding S.A. reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Itau Unibanco Holding S.A. sold 226 Fate Therapeutics shares in Q2 2023, an estimated $1.29K.
  • Itau Unibanco Holding S.A. first reported a position in Fate Therapeutics in Q2 2021 and held it in 8 quarters.
  • Itau Unibanco Holding S.A.'s Fate Therapeutics position peaked at $24K in Q2 2021.
  • 188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q2 2023, filed 14 Aug 2023.